Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 7/20 | 0.51 |
| ▸ | NPY1R | P25929 | 5/20 | 0.51 |
| ▸ | NPY2R | P49146 | 3/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.45 |
| ▸ | MME | P08473 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30034864 | 0.91 | NPY1R (0.53) | NPY4RNPY1RNPY2RFOLH1OPRM1 | |
| SCHEMBL30400489 | 0.91 | NPY4R (0.52) | NPY4RNPY1RNPY2RFOLH1OPRM1 | |
| SCHEMBL31020753 | 0.90 | NPY1R (0.46) | NPY4RNPY1RNPY2RFOLH1OPRM1 | |
| SCHEMBL29705780 | 0.90 | OPRD1 (0.54) | NPY4RNPY1RNPY2RFOLH1OPRM1 | |
| SCHEMBL30729668 | 0.87 | FOLH1 (0.53) | NPY4RNPY1RNPY2RFOLH1OPRM1 | |
| SCHEMBL30729665 | 0.87 | FOLH1 (0.53) | NPY4RNPY1RNPY2RFOLH1OPRM1 | |
| SCHEMBL29815237 | 0.87 | NPY4R (0.51) | NPY4RNPY1RNPY2RFOLH1OPRM1 | |
| SCHEMBL29993760 | 0.87 | NPY4R (0.53) | NPY4RNPY1RNPY2RFOLH1OPRM1 | |
| SCHEMBL30629018 | 0.87 | MME (0.47) | NPY4RNPY1RNPY2ROPRM1OPRD1 | |
| SCHEMBL3100946 | 0.86 | OPRM1 (0.47) | NPY4RNPY1RNPY2RFOLH1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220242964-A1 | COMPOSITIONS AND METHODS FOR REGULATING ERYTHROPOIESIS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2022-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220242964-A1 | COMPOSITIONS AND METHODS FOR REGULATING ERYTHROPOIESIS | EPOR, CD47, CD44 | NPY4R 2616/4885NPY1R 2794/4885NPY2R 2869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.